Compile Data Set for Download or QSAR
maximum 50k data
Found 42 Enz. Inhib. hit(s) with all data for entry = 479
TargetHypoxia-inducible factor 1-alpha(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM271458(2-(4-hydroxy-1-methyl-2-oxo-7-phenoxy-1,2-dihydroq...)
Affinity DataEC50:  5.35E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHypoxia-inducible factor 1-alpha(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM271499(2-(7-(2-chlorophenoxy)-4-hydroxy-1-methyl-2-oxo-1,...)
Affinity DataEC50:  6.60E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHypoxia-inducible factor 1-alpha(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM271460(2-(4-hydroxy-1-methyl-2-oxo-6-phenoxy-1,2-dihydroq...)
Affinity DataEC50:  4.00E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHypoxia-inducible factor 1-alpha(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM271461(2-(6-((1H-indol-1-yl)sulfonyl)-4-hydroxy-1-methyl-...)
Affinity DataEC50:  6.83E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHypoxia-inducible factor 1-alpha(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM271462(2-(4-hydroxy-1-methyl-7-(naphthalen-2-yloxy)-2-oxo...)
Affinity DataEC50:  1.63E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHypoxia-inducible factor 1-alpha(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM271463(2-(4-hydroxy-1-methyl-6-(naphthalen-2-yloxy)-2-oxo...)
Affinity DataEC50:  2.52E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHypoxia-inducible factor 1-alpha(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM271464(2-(6-(benzhydryl(methyl)carbamoyl)-4-hydroxy-1-met...)
Affinity DataEC50:  1.02E+4nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHypoxia-inducible factor 1-alpha(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM271465(2-(7-(3-chlorophenoxy)-4-hydroxy-1-methyl-2-oxo-1,...)
Affinity DataEC50:  4.24E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHypoxia-inducible factor 1-alpha(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM271466(2-(7-(4-chlorophenoxy)-4-hydroxy-1-methyl-2-oxo-1,...)
Affinity DataEC50:  7.10E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHypoxia-inducible factor 1-alpha(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM271467(2-(7-(2,3-difluorophenoxy)-4-hydroxy-1-methyl-2-ox...)
Affinity DataEC50:  1.03E+4nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHypoxia-inducible factor 1-alpha(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM271468(2-(7-(2,4-difluorophenoxy)-4-hydroxy-1-methyl-2-ox...)
Affinity DataEC50:  6.92E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHypoxia-inducible factor 1-alpha(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM271469(2-(7-(2,6-difluorophenoxy)-4-hydroxy-1-methyl-2-ox...)
Affinity DataEC50:  8.83E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHypoxia-inducible factor 1-alpha(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM271470(2-(7-(3,4-difluorophenoxy)-4-hydroxy-1-methyl-2-ox...)
Affinity DataEC50:  3.16E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHypoxia-inducible factor 1-alpha(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM271471(2-(7-(3,5-difluorophenoxy)-4-hydroxy-1-methyl-2-ox...)
Affinity DataEC50:  6.28E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHypoxia-inducible factor 1-alpha(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM271472(2-(7-(2,5-difluorophenoxy)-4-hydroxy-1-methyl-2-ox...)
Affinity DataEC50:  2.26E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHypoxia-inducible factor 1-alpha(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM271473(2-(7-(3-chloro-2-fluorophenoxy)-4-hydroxy-1-methyl...)
Affinity DataEC50:  3.75E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHypoxia-inducible factor 1-alpha(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM271474(2-(7-(4-chloro-2-fluorophenoxy)-4-hydroxy-1-methyl...)
Affinity DataEC50:  5.75E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHypoxia-inducible factor 1-alpha(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM271475(2-(7-(5-chloro-2-fluorophenoxy)-4-hydroxy-1-methyl...)
Affinity DataEC50:  4.18E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHypoxia-inducible factor 1-alpha(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM271476(2-(7-(2-chloro-6-fluorophenoxy)-4-hydroxy-1-methyl...)
Affinity DataEC50:  9.23E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHypoxia-inducible factor 1-alpha(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM271477(2-(7-(2-chloro-3-fluorophenoxy)-4-hydroxy-1-methyl...)
Affinity DataEC50:  9.53E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHypoxia-inducible factor 1-alpha(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM271478(2-(7-(4-chloro-3-fluorophenoxy)-4-hydroxy-1-methyl...)
Affinity DataEC50:  1.02E+4nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHypoxia-inducible factor 1-alpha(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM271479(2-(7-(3-chloro-5-fluorophenoxy)-4-hydroxy-1-methyl...)
Affinity DataEC50:  1.35E+4nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHypoxia-inducible factor 1-alpha(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM271480(2-(7-(2-chloro-5-fluorophenoxy)-4-hydroxy-1-methyl...)
Affinity DataEC50:  6.85E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHypoxia-inducible factor 1-alpha(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM271481(2-(7-(2-chloro-4-fluorophenoxy)-4-hydroxy-1-methyl...)
Affinity DataEC50:  1.51E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHypoxia-inducible factor 1-alpha(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM271482(2-(7-(3-chloro-4-fluorophenoxy)-4-hydroxy-1-methyl...)
Affinity DataEC50:  1.02E+4nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHypoxia-inducible factor 1-alpha(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM271483(2-(7-(2,3-dichlorophenoxy)-4-hydroxy-1-methyl-2-ox...)
Affinity DataEC50:  1.97E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHypoxia-inducible factor 1-alpha(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM271484(2-(7-(2,4-dichlorophenoxy)-4-hydroxy-1-methyl-2-ox...)
Affinity DataEC50:  4.15E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHypoxia-inducible factor 1-alpha(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM271485(2-(7-(2,6-dichlorophenoxy)-4-hydroxy-1-methyl-2-ox...)
Affinity DataEC50:  3.63E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHypoxia-inducible factor 1-alpha(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM271486(2-(7-(3,4-dichlorophenoxy)-4-hydroxy-1-methyl-2-ox...)
Affinity DataEC50:  2.56E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHypoxia-inducible factor 1-alpha(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM271487(2-(7-(3,5-dichlorophenoxy)-4-hydroxy-1-methyl-2-ox...)
Affinity DataEC50:  2.02E+4nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHypoxia-inducible factor 1-alpha(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM271488(2-(7-(2,5-dichlorophenoxy)-4-hydroxy-1-methyl-2-ox...)
Affinity DataEC50:  2.25E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHypoxia-inducible factor 1-alpha(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM271489(2-(4-hydroxy-7-(4-methoxyphenoxy)-1-methyl-2-oxo-1...)
Affinity DataEC50:  2.95E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHypoxia-inducible factor 1-alpha(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM271490(2-(4-hydroxy-7-(3-methoxyphenoxy)-1-methyl-2-oxo-1...)
Affinity DataEC50:  6.26E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHypoxia-inducible factor 1-alpha(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM271491(2-(4-hydroxy-7-(2-methoxyphenoxy)-1-methyl-2-oxo-1...)
Affinity DataEC50:  8.85E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHypoxia-inducible factor 1-alpha(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM271492(2-(6-fluoro-4-hydroxy-1-methyl-2-oxo-7-phenoxy-1,2...)
Affinity DataEC50:  4.89E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHypoxia-inducible factor 1-alpha(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM271493(2-(4-hydroxy-1-methyl-2-oxo-7-(2-(trifluoromethoxy...)
Affinity DataEC50:  4.06E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHypoxia-inducible factor 1-alpha(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM271494(2-(1-(cyclopropylethyl)-4-hydroxy-2-oxo-7-phenoxy-...)
Affinity DataEC50:  3.34E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHypoxia-inducible factor 1-alpha(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM271495(2-(4-hydroxy-1-methyl-2-oxo-7-(pyridin-4-yloxy)-1,...)
Affinity DataEC50:  2.89E+4nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHypoxia-inducible factor 1-alpha(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM271496(2-(7-(2-fluorophenoxy)-4-hydroxy-1-methyl-2-oxo-1,...)
Affinity DataEC50:  6.02E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHypoxia-inducible factor 1-alpha(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM271497(2-(7-(3-fluorophenoxy)-4-hydroxy-1-methyl-2-oxo-1,...)
Affinity DataEC50:  3.61E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHypoxia-inducible factor 1-alpha(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM271498(2-(7-(4-fluorophenoxy)-4-hydroxy-1-methyl-2-oxo-1,...)
Affinity DataEC50:  3.92E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHypoxia-inducible factor 1-alpha(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM271459(2-(1-(cyclopropylmethyl)-4-hydroxy-2-oxo-7-phenoxy...)
Affinity DataEC50:  5.00E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent